india

Indian Pharma Manufacturing: Serving the World

Indian pharma production is growing rapidly - boosted by the Modi government’s ‘Make in India’ campaign – and both Indian companies and multinationals implanted in the world’s second most populous…

Africa: The Launchpad for Indian Pharma

Although most industry observers expect that Indian pharma exports to the US will pick up again in the coming…

India: Creating An Innovative Healthcare Ecosystem

At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based…

India: Still a Land of Opportunity for MNCs

For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India…

In Conversation

Dr. Letitia Robinson, Director of the US FDA India Office, provides insights into the main goals and responsibilities of the FDA in India and documents the US FDA’s collaboration efforts with its Indian regulatory counterparts. Could you introduce to our international readers the US FDA’s Office of International Programs and the Indian Office in particular? “Indian regulators have become important…

Satyanarayana Chava – CEO, Laurus Labs, India

Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has…

Meeting US FDA Standards Across the Board in India

In a context where even well-established, multi-billion-dollar domestic companies have received warning letters…

Colombia: The Great Indian Investment Wave

With the onset of universal public healthcare, new types of foreign actors have been spying fresh opportunities to…

MNCs’ Healthcare Access Initiatives in India

With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to…

10 Pharma Leaders to Know in India

Indian pharma companies provide affordable generic drugs to patients in almost all countries across the globe,…

Indian Biosimilars: Going Global

Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven…

India: Good Endings, Good Beginnings

What probably best explains the contrasts in the Indian pharmaceutical landscape is the fact that India can take…

Gender Diversity in Indian Pharma

India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the…

Quality Compliance in Indian Pharma: The Learning Curve

One issue grinding the gears of the Indian pharmaceutical industry over recent years has been quality compliance.…

Healthcare Politics in 2019

Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for…